Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
finerenone + empagliflozin
- Development stage
- Phase 4
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Combination of **finerenone**, a nonsteroidal mineralocorticoid receptor antagonist (nsMRA), and **empagliflozin**, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, used together for patients with **chronic kidney disease (CKD) and type 2 diabetes**. Finerenone selectively blocks mineralocorticoid receptors, providing anti-inflammatory and anti-fibrotic cardio-renal protection. Empagliflozin inhibits SGLT2 in the kidney, reducing glucose reabsorption and exerting nephroprotective and cardioprotective effects. The CONFIDENCE trial demonstrated that this combination significantly reduces urinary albumin-to-creatinine ratio (UACR), indicating a reduction in albuminuria and greater kidney protection than either agent alone. The combination shows an additive or synergistic effect on kidney outcomes, with an acceptable safety profile in the target population[1][3][4][5][7].
- Brand names
- Kerendia + Jardiance
- Other names
- empagliflozin + finerenoneempagliflozin + Kerendiafinerenone + empagliflozinJardiance + finerenoneKerendia + empagliflozin
02
Targets
MR (Mineralocorticoid receptor)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on finerenone + empagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on finerenone + empagliflozin.